恩度联合顺铂治疗恶性腹腔积液的疗效及安全性评估

doi:10.3969/j.issn.1674-5817.2018.03.006

摘要/Abstract

摘要： 目的评估恩度联合顺铂治疗恶性腹腔积液的疗效及增效机制。方法建立小鼠H22肿瘤腹水模型,随机分为生理盐水组、单独恩度组(10 mg/kg/d)、单独顺铂组(2.5 mg/kg/5 d)和恩度顺铂联合组1(每日给予恩度)、联合组2(隔日给予恩度),每组18只。治疗结束后每组取6只动物腹水样品进行蛋白浓度、红细胞数量、肿瘤细胞数量、肿瘤细胞凋亡比例测定,其余小鼠观察各组荷瘤寿命,以对照组基本死亡为实验结束的节点。结果 (1)与生理盐水组相比,恩度、顺铂单独或联合处理组给药期间体质量、腹围增长速度和腹水量均显著降低(P<0.01),其中联合组小鼠体质量、腹围增长速度和腹水量显著低于单纯恩度或顺铂组小鼠(P<0.01)。(2)联合组2小鼠腹水中红细胞含量显著低于生理盐水组、单纯恩度组和单纯顺铂组(P<0.01)。生理盐水组小鼠腹水中肿瘤细胞数量显著高于恩度、顺铂单独或联合处理组(P<0.01)。生理盐水组小鼠腹水中肿瘤细胞凋亡率显著低于单纯顺铂组、联合组1和联合组2(P<0.01),但与单纯恩度组相比差异无统计学意义。(3)Logrank分析显示恩度联合顺铂对于小鼠的生存时间有显著延长作用(P<0.01)。结论恩度和顺铂联用具有协同作用,可有效抑制小鼠腹水产生,减少腹水中红细胞渗透率,延长小鼠生存期; 其中每日给予恩度效果优于隔日给予。

关键词: 顺铂, 恩度, 恶性腹腔积液, 疗效

Abstract: Objective To evaluate efficacy of the combination of Endostar and cisplatin in malignant peritoneal effusion and its underlying mechanism(s).Methods The H22 tumor ascites mice model was successfully established and randomly divided into control group,Endostar group (10 mg/kg/day),cisplatin group (2.5 mg/kg/5 day),combination group 1(Endostar was given every day) and combination group2 (Endostar was given every 2 days).Each group consist of 18 animals.At the end of the treatment,6 animals in each group were sacrificed.The ascites volume,erythrocytes number in ascites,number and apoptosis rate of tumor cells in ascites were recorded.The survival time was observed and the endpoint was determined as all control animals died.Results (1) Compared with the saline group,the body weight,the growth rate of the abdominal circumference and the ascites volume were significantly decreased in the Endostar group,cisplatin group and the Endostar-cisplatin combination group (P<0.01).The growth rate in the body weight and abdominal circumference and ascites volume were significantly lower than those in the Endostar group and the cisplatin group (P<0.01).(2) The number of erythrocytes in Endostar-cisplatin combination group 2 was significantly lower than that in saline group,Endostar group and cisplatin group (P<0.01).The number of tumor cells in the ascites of the saline group was significantly higher than that in the Endostar group,the cisplatin group and the Endostar-cisplatin combination group (P<0.01).The apoptosis rate of tumor cells in Endostar-cisplatin combined group was significantly higher than that in saline group and Endostar group (P<0.01),There was no significant difference between control and cisplatin group.(3) Log-rank analysis showed that combination group had a significant effect on the survival time of mice (P<0.01).Conclusion The combination of Endostar and cisplatin effectively inhibits the production of ascites,reduces the red blood cell permeability,and induces the apoptosis of tumor cells in ascites,which may extend the survival time of animal.The two drugs has synergistic effect.The effect of daily administration of Endostar is better than administration each other day.

Key words: Endostar, Cisplatin, Malignant peritoneal effusion, Efficacy evaluation

中图分类号:

Q95-33

严俊, 卢国丰, 王纯, 闵新. 恩度联合顺铂治疗恶性腹腔积液的疗效及安全性评估[J]. 实验动物与比较医学, 2018, 38(3): 194-201.

YAN Jun, LU Guo-feng, WANG Chun, MIN Xin. Efficacy and Safety Evaluation of Combination Treathment with Endostar and Cisplatin in Malignant Peritoneal Effusion[J]. Laboratory Animal and Comparative Medicine, 2018, 38(3): 194-201.

参考文献

[1] Le Corvec M,Jezequel C,Monbet V,et al.Mid-infrared spectroscopy of serum,a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis[J].PLoS One,2017,12(10):e0185997.
[2] Bekes I,Friedl TW,Kohler T,et al.Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion,thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?[J].Mol Cancer,2016,15:13.
[3] O'Reilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth[J].Cell,1997,88(2):277-285.
[4] Zhang YC,Li XM,Yu Z,et al.Efficacy of pEgr-1-endostatin combined with ionizing radiation on hypoxic conditions in nude mice bearing SKOV3 ovarian carcinoma[J].Oncol Lett,2017,13(3):1101-1108.
[5] Ren Z,Wang Y,Jiang W,et al.Anti-tumor effect of a novel soluble recombinant human endostatin:administered as a single agent or in combination with chemotherapy agents in mouse tumor models[J].PLoS One,2014,9(9):e107823.
[6] Tong Y,Zhong K,Tian H,et al.Characterization of a monoPEG20000-Endostar[J].Int J Biol Macromol,2010,46(3):331-336.
[7] Zhang Q,Cao J,Xue K,et al.Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma[J].Onco Targets Ther,2017,10:145-151.
[8] Biaoxue R,Xiguang C,Hua L,et al.Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions:a systematic evaluation and meta-analysis[J].BMC Cancer,2016,16(1):888.
[9] Hochster HS,Piccart M.Intraperitoneal chemotherapy:belly bath or pain in the side[J].Eur J Cancer Clin Oncol,1987,23(3):259-261.
[10] Hirayama N,Tabata C,Tabata R,et al.Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma[J].Respir Med,2011,105(1):137-142.
[11] Abdel-Razik A,Mousa N,Elalfy H,et al.A novel combination of C-reactive protein and vascular endothelial growth factor in differential diagnosis of ascites[J].J Gastrointest Cancer,2017,48(1):50-57.
[12] Yin T,Wang G,He S,et al.Malignant pleural effusion and ascites induce epithelial-mesenchymal transition and cancer stem-like cell properties via the vascular endothelial growth factor (VEGF)/phosphatidylinositol 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) Pathway[J].J Biol Chem,2016,291(52):26750-26761.
[13] Yang L,Zhang Y,Cheng L,et al.Mesenchymal stem cells engineered to secrete pigment epithelium-derived factor inhibit tumor metastasis and the formation of malignant ascites in a murine colorectal peritoneal carcinomatosis model[J].Hum Gene Ther,2016,27(3):267-77.
[14] Wei H,Qin S,Yin X,et al.Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites[J].Oncol Lett,2015,9(6):2694-2700.
[15] Mostmans Y,Cutolo M,Giddelo C,et al.The role of endothelial cells in the vasculopathy of systemic sclerosis:A systematic review[J].Autoimmun Rev,2017,16(8):774-786.
[16] Han Q,Fu Y,Zhou H,et al.Contributions of Zn(II)-binding to the structural stability of endostatin[J].FEBS Lett,2007,581(16):3027-3032.
[17] Mohajeri A,Sanaei S,Kiafar F,et al.The challenges of recombinant endostatin in clinical application:focus on the different expression systems and molecular bioengineering[J].Adv Pharm Bull,2017,7(1):21-34.